Wir sind mit live! Mehr erfahren

NeoGenomics

NEO

Börsenwert 2,14 Mrd. $

16,65 USD

-0,60

3,48 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

16,66

+0,01

0,06 %

1 Tag

-3,48 %

5 Tage

1,83 %

1 Monat

-12,09 %

3 Monate

12,2 %

6 Monate

104,04 %

Seit Jahresbeginn

41,58 %

1 Jahr

61,96 %

5 Jahre

-61,86 %

10 Jahre

121,7 %

Profil: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Mitarbeiter: 2.500

Gesundheitswesen Diagnostik & Research

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 26,7 %

Neutral 66,7 %

Negativ 6,7 %

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

What's Going On With NeoGenomics Stock Tuesday?

Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026.

What's Going On With NeoGenomics Stock Tuesday?

Investors Business Daily

Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives

Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.

Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

Neo Performance Materials Q2 Earnings Call Highlights

Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.

Neo Performance Materials Q2 Earnings Call Highlights

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt